Neglected Burning Rock charms investors with high margins, narrowing losses
The cancer diagnostics company’s revenue rose slightly in the third quarter, as its gross margin rose by nearly 4 percentage points Key Takeaways: Burning Rock’s revenue rose 2.3% in the…
BRIEF: Legend Biotech considers second listing outside U.S.
Cancer treatment maker Legend Biotech Corp. (LEGN.US) is weighing a second listing to complement its existing one in the U.S., with possible venues including Hong Kong, Singapore and London, Bloomberg…
BRIEF: Legend Biotech’s revenue rises 36% in second quarter
Drug maker Legend Biotech Corp. (LEGN.US) on Monday reported strong revenue growth in the second quarter of 2025 as its core cancer drug gained traction. But its net loss also…
BRIEF: Hutchmed’s revenue falls in first half of 2025
Drug maker Hutchmed (China) Ltd. (HCM.US; 0013.HK) reported its revenue fell in the first half of 2025, as a small gain for its best-selling drug failed to offset declines for…
BRIEF: Bayzed Health jumps in Hong Kong trading debut
Shares of cancer hospital operator Bayzed Health Group Inc. (2609.HK) jumped in their Hong Kong trading debut on Monday, as the company raised HK$562 million ($72 million) in an IPO that received…
Kintor Pharma shifts from cancer drugs to cosmetics as funds run low
The cash-strapped biotech has begun generating its first revenue from over-the-counter cosmetic treatments, as it pivots away from its original oncology drugs Key Takeaways: Kintor Pharma is shifting from its…
Everest Medicines drives growth with AI-powered mRNA pipeline
The company said the U.S. FDA has cleared the IND application for its self-developed EVM14, a tumor-associated antigen vaccine Key Takeaways: The FDA has cleared Everest Medicine’s EVM14 cancer vaccine…
Recent Articles
RELATED ARTICLES
-
Years of losses, thin profit margins leave 160 Health feeling down
2656.HK - With so many new IPOs, Quantgroup looks better left for high-risk investors
-
MoneyHero’s insurance and wealth shift boosts margins as it approaches profitability
MNY.US
-
Sany hopes Hong Kong investors see it as global high-tech heavy hitter
6031.HK600031.SHG
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
-
Nio’s road to profitability obscured in haze of losses
9866.HKNIO.US
- ShanH seeks IPO recharge after years of losses
